Part-Time

Registered Nurse

Transplant Clinic

Deadline 6/30/27
Fred Hutchinson Cancer Center

Fred Hutchinson Cancer Center

1,001-5,000 employees

Nonprofit cancer treatment, research, and trials

Compensation Overview

$47.64 - $88.19/hr

+ Shift Differentials + Relocation Assistance + Advanced Degree Premium + Preceptor Pay + Certification Pay

No H1B Sponsorship

Seattle, WA, USA

In Person

On-site role based in Seattle, Washington.

Category
Medical, Clinical & Veterinary (1)

Get referred to Fred Hutchinson Cancer Center

Find people who can refer or advise you

Requirements
  • Graduate from an accredited school of nursing
  • Current Washington State Registered Nurse license or current Nurse Licensure Compact multistate license; and MSL primary state of residence must be updated to WA within 60 days of hire
  • Waiver of MSL requirement may be approved under specific circumstances
  • Applicants that do not have previous oncology experience will be provided additional training and support
  • Current BLS Health Care Provider Card (AHA) and renewal required every two years
  • Additional certification may be required dependent upon department
  • Critical thinking; the ability to practice the cognitive skills of analyzing, applying standards, discriminating, information seeking, logical reasoning, predicting, and transforming knowledge
  • Ability to develop clinical judgment
  • Time management skills; the ability to organize and manage time and tasks independently
  • Ability to communicate effectively by looking and listening for cues, asking open-ended questions, exploring cues, using pauses, screening responses, and clarifying response
  • Ability to effectively listen by using reflecting, acknowledging, summarizing, empathizing, and paraphrasing skill
  • Ability to effectively provide information by checking what information the person knows already, giving small amounts of information at a time, using clear terms and avoiding jargon, avoiding detail unless it is requested, checking for understanding, and pausing and waiting for a response
Responsibilities
  • Assesses physical, emotional, social, and spiritual needs and evaluates patients’ adaptation to health changes
  • Develops a plan of care based on patients’ disease, symptoms, and response to treatment
  • Educates patients, families, and caregivers on disease processes, treatment, side effects and symptom management
  • Coordinates with inter-disciplinary team to ensure continuity of care
  • Refers patients, families and caregivers as appropriate to other clinical resources/professionals such as social work, home health care, clinical nutrition, etc.
  • Implements, evaluates and modifies plan of care
  • Integrates research and evidence based knowledge into clinical practice
  • Performs comprehensive initial assessment of patient, family and caregiver
  • Performs ongoing assessment of patient, family and caregiver as patient progresses through Transplant process
  • Monitors patient response to therapies, including lab values and symptom assessment, in collaboration with the medical, nutrition and pharmacy staff
  • Provides psychosocial support to patients and families
  • Functions as resource for rotating physician staff regarding standard practice and operations in the clinic
  • Reviews all orders written by the medical staff
  • Communicates hospital admissions to the Charge RN
  • Coordinate home infusions provided by outside Home Infusion agencies after initial referral by Transition RNs
  • Provide continuity of nursing care by communicating effectively with Charge, Evening, Weekend, Infusion
  • Room, Procedure, Triage, and Inpatient RN’s
  • Documents all assessments, teaching, response to therapies and plans of care in a timely manner
  • Keeps patient Kardex up to date
  • Functions as primary telephone contact for patients and their caregivers
  • Participates with all disciplines in daily rounds to plan and coordinate patient care
  • Provides initial education and Clinic orientation. Reviews Patient Resource Manual with patient and family at arrival visit
  • Assumes primary responsibility for chemotherapy teaching with patients and caregivers
  • Assumes primary responsibility for patient education regarding medications and therapies, including home infusions
  • Assumes primary responsibility for patient education regarding symptom management
  • Assumes primary responsibility for departure teaching when patient is leaving the Acute Transplant Program
  • Acts as patient advocate in coordination of research consent forms
  • Assists in obtaining research data in conjunction with patient care data
  • Maintains a working knowledge of current protocols related to the patient population with whom they work. Knows research resources and how to access
  • Participates in Committees and Task Forces to review and improve current standards
  • Serves as a resource to other nurses caring for patients undergoing BMT transplant
  • Flexible in incorporating patient care outside own team assignment to assist with patient care needs in other areas of clinic
  • Informs Nurse Manager of high-risk patient situations or operational issues
  • Communicates in a respectful and effective manner with other staff
  • Demonstrates appropriate problem solving when working with other departments
  • Participates in continuing education programs
  • Keeps current in area of expertise through journals, books, and conferences
  • Regular attendance and punctuality are essential functions of this job in order to carry out the primary responsibilities.
Desired Qualifications
  • Bachelor of Science in Nursing
  • Two years of nursing experience preferred
Fred Hutchinson Cancer Center

Fred Hutchinson Cancer Center

View

Fred Hutchinson Cancer Center is a nonprofit cancer treatment and research institute serving the Pacific Northwest and beyond. It provides a full range of cancer care, including treatments that may not be available elsewhere, and offers patients the chance to participate in clinical trials. The center accomplishes its work through a combination of patient care, research grants, and fundraising, and collaborates with UW Medicine and other regional providers to extend its reach. Internationally, it operates facilities in Uganda and South Africa to advance research and collaboration. The organization’s revenue comes from patient services, grants, and fundraising events. Its central goal is to eliminate cancer and related diseases by improving treatments and ultimately finding a cure.

Company Size

1,001-5,000

Company Stage

Grant

Total Funding

$300K

Headquarters

Seattle, Washington

Founded

1975

Get referred to Fred Hutchinson Cancer Center

Find people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Ai2, Google Cloud add $20M to Cancer AI Alliance's $40M funding.
  • Global sites in Uganda, South Africa enable diverse AI training data.
  • NCI-designated center since 1973 drives research grants, fundraising.

What critics are saying

  • AWS, Microsoft, NVIDIA cut commitments, halting 2025 AI results.
  • Dana-Farber, MSK erode Fred Hutch's precision oncology referrals.
  • NIH grants lapse, Obliteride donors drop in recession by 2027.

What makes Fred Hutchinson Cancer Center unique

  • Fred Hutch leads Cancer AI Alliance coordinating Dana-Farber, MSK, Johns Hopkins.
  • Offers 750+ active clinical trials, most in Pacific Northwest.
  • Pioneers precision oncology via Stuart and Molly Sloan Institute.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Health Savings Account/Flexible Spending Account

Paid Vacation

Paid Sick Leave

Paid Holidays

Paid Parental Leave

Sabbatical Leave

Tuition Reimbursement

Company News

Ensoma
Jul 16th, 2026
Ensoma Launches to Pioneer Next-Generation In Vivo Approach to Deliver First “Off-the-shelf” Genomic Medicines

Company’s Engenious™ Vectors Delivered without Stem Cell Collection or Myeloablative Conditioning in Outpatient and Low-resource Settings, Enabling Access Worldwide

GeekWire
Apr 17th, 2025
Tech Moves: Smartsheet Names Chief Product Officer; Meta Vet Joins Tech Alliance; And More

Tech Moves covers notable hires, promotions and personnel changes in the Pacific NW tech community. Submissions: [email protected] Arora. (Smartsheet Photo)— Pratima Arora has been named chief product officer at Smartsheet, a new senior executive role at the Bellevue, Wash.-based enterprise software giant.A longtime product and technology leader, Arora will be responsible for Smartsheet’s product management, product marketing, user experience, pricing and packaging, and digital and product partnerships.She previously held senior leadership roles at Atlassian and Salesforce, and was most recently the chief product and technology officer at Chainalysis.“After a fantastic 4-month break to recharge, spend quality time with family, and dive deep into the world of GenAI, I’m energized and ready for what’s next,” Arora said on LinkedIn. “There’s no better place than Smartsheet to begin this new chapter. With a strong foundation, a passionate customer base, and a unique opportunity to reimagine collaborative work through AI, the road ahead is full of possibility.”Smartsheet also announced that Nick Dunn, an eight-year veteran of the company, is now general counsel, responsible for leading the company’s legal, privacy, and risk functions, including corporate governance initiatives.Launched in 2005, Smartsheet makes cloud-based enterprise work management technologies for managing and tracking projects, collaborating, storing data, and automating and assigning tasks, among other capabilities. It serves 85% of the Fortune 500 as customers

PR Newswire
Apr 4th, 2025
Google Cloud And Ai2 Commit $20M To Advance Ai-Powered Research For The Cancer Ai Alliance

Google Cloud to provide advanced and secure technology, while Ai2 to lead AI training and development for AI cancer modelsSEATTLE and SUNNYVALE, Calif., April 4, 2025 /PRNewswire/ -- Today, Google Cloud and Ai2 announced they have partnered with the Cancer AI Alliance (CAIA), a pioneering consortium uniting leading cancer research institutions and technology companies to harness artificial intelligence (AI) in the fight against cancer. Google Cloud and Ai2 are each giving $10 million to the initiative and providing access to technology solutions that will help speed scientific discovery. Google Cloud will power planet-scale AI infrastructure and data analytics tools, while Ai2 will provide critical expertise in training large-scale models focusing on cancer research

GeekWire
Apr 4th, 2025
Ai2 And Google Cloud Join Cancer Ai Alliance With A Total Of $20M In Commitments

Inside the Allen Institute for AI in Seattle. (GeekWire File Photo / Todd Bishop)The Allen Institute for AI (Ai2) is joining a high-profile national effort to accelerate cancer research using artificial intelligence, committing $10 million in researcher time and technical expertise to the Cancer AI Alliance, a consortium led by the Fred Hutch Cancer Center.Google Cloud is also committing $10 million in resources to the effort, planning to provide computing infrastructure and tools to help process large volumes of cancer data. They say the goal is to create a novel AI infrastructure that supports the training and deployment of AI models across institutions while maintaining data security and privacy standards for patients.The Cancer AI Alliance was announced in October 2024 as a joint effort among four major cancer centers: Fred Hutch, Dana-Farber, Memorial Sloan Kettering, and Johns Hopkins. Backed by more than $40 million in initial support from AWS, Microsoft, NVIDIA, Deloitte, and Slalom, the project aims to use artificial intelligence to analyze large volumes of cancer data across institutions. Seattle-based Fred Hutch is serving as the lead coordinating center.Ai2 CEO Ali Farhadi in his Seattle office. (GeekWire File Photo / Todd Bishop)In a previous interview with GeekWire, Ai2 CEO Ali Farhadi said the Cancer AI Alliance represents the kind of real-world challenge that needs customized, domain-specific AI models. The Seattle-based AI institute focuses on open-source artificial intelligence technologies.Farhadi said Ai2’s role in the Cancer AI Alliance reflects Ai2’s goal to apply cutting-edge research where it can have the most tangible impact on the world.“Any step in the right direction in that space is going to be a risk worth taking, and that’s the kind of impact that we’re after,” Farhadi said, explaining Ai2’s ambitions for 2025 on the GeekWire Podcast. “If you’re actually trying to solve a real problem, there is no turnkey solution.”The Cancer AI Alliance has said it expects initial research results by the end of 2025

GeekWire
Mar 18th, 2025
Geekwire Awards: Health Innovation Of The Year Field Is Dominated By Finalists Battling Cancer

The 2025 GeekWire Award finalists for Health Innovation of the Year are dominated by ventures that aim to outwit cancer with groundbreaking new technologies. The contenders range from a newly formed startup to a leading U.S. cancer institute and companies in between. Joining the cohort is a business with technology to help healthcare providers better manage appointments and access to providers.This awards category recognizes pioneering health, life science, biotechnology or medical breakthroughs that hold great promise for improving peoples’ lives and enhancing the healthcare system.The finalists are Archon Biosciences, DexCare, Fred Hutch Cancer Center, Talus Bioscience and Umoja Biopharma.Last year’s winner was CalmWave, a Seattle health-tech startup that created a system for making sense of the alarms triggered by the devices that monitor hospital ICU patients.Continue reading for details on each of this year’s finalists, and vote here or below.Archon BiosciencesArchon Biosciences emerged from stealth last October with $20 million in funding. The Seattle biotech company is running with technology developed in the lab of University of Washington biochemist and Nobel Prize winner David Baker.Archon’s proprietary protein structures, known as Antibody Cages or AbCs, combine two biomedical tools — naturally occurring antibodies and custom-designed proteins — to create a single new protein structure. These protein structures, or AbCs, are optimized with the aid of generative AI to travel in the body in controllable ways and engage with target cells in a more specific manner.“What we like to say is, it’s not whether you’re given a drug, it’s how you’re given it,” said CEO and co-founder James Lazarovits